Synthetic therapeutic peptides (STP) are intensively studied as new-generation drugs, characterized by high purity, biocompatibility, selectivity and stereochemical control. However, most of the studies are focussed on the bioactivity of STP without considering how the formulation actually used for therapy administration could alter the physico-chemical properties of the active principle. The aggregation properties of a 20-mer STP (Ac-His-Ala-Arg-Ile-Lys-D-Pro-Thr-Phe-Arg-Arg-D-Leu-Lys-Trp-Lys-Tyr-Lys-Gly-Lys-Phe-Trp-NH ), showing antitumor activity, were investigated by optical spectroscopy and atomic force microscopy imaging, as itself (CIGB552) and in its therapeutic formulation (CIGB552TF). It has found that the therapeutic formulation deeply affects the aggregation properties of the investigated peptide and the morphology of the aggregates formed on mica by deposition of CIGB552 and CIGB552TF millimolar solutions. Molecular dynamics simulations studied the first steps of CIGB552 aggregation under physiological ionic strength conditions (NaCl 150 mM), showing that peptide oligomers, from dimers to tetramers, are preferentially formed in this environment. Interestingly, cell viability assays performed on H-460 cell lines indicate a major antiproliferative activity of the peptide in its therapeutic formulation with respect to the peptide aqueous solution.

Download full-text PDF

Source
http://dx.doi.org/10.1002/psc.3356DOI Listing

Publication Analysis

Top Keywords

therapeutic formulation
12
molecular dynamics
8
aggregation properties
8
formulation
6
peptide
5
formulation matters!
4
matters! spectroscopic
4
spectroscopic molecular
4
dynamics investigation
4
investigation peptide
4

Similar Publications

Nanocurcumin in myocardial infarction therapy: emerging trends and future directions.

Front Bioeng Biotechnol

January 2025

Department of Cardiology, Yantaishan Hospital, Yantai, Shandong, China.

Myocardial infarction (MI) is the leading cause of morbidity and mortality worldwide. Curcumin has been observed to significantly reduce pathological processes associated with MI. Its clinical application is limited due to its low bioavailability, rapid degradation, and poor solubility.

View Article and Find Full Text PDF

The utilization of quercetin nanoparticles as a novel therapeutic strategy has garnered significant attention in recent years. These nanoparticles offer a unique approach to enhancing delivery and effectiveness while overcoming the drawbacks of quercetin. By exploiting the advantages of nanotechnology, such as increased stability and improved bioavailability, quercetin nanoparticles hold significant potential for developing innovative treatments across various medical fields.

View Article and Find Full Text PDF

Objective: This study aims to explore the therapeutic mechanism of Massa Medicata Fermentata (MMF) with different formulations on spleen deficiency constipation in mice by analyzing gastrointestinal hormones, D-xylose, intestinal microbiota, and intestinal enzyme activities.

Methods: A spleen deficiency constipation model was established using an oral administration of Sennae Folium decoction combined with controlled diet and water intake. After successful model establishment, the mice with spleen deficiency constipation were treated with MMF S1, S2, S3.

View Article and Find Full Text PDF

Background: Itraconazole (ICZ) has been approved by the FDA to treat many fungal infections including, blastomycosis, histoplasmosis, and aspergillosis. ICZ can be also used as prophylaxis in the population who are at high risk for developing systemic fungal infections, such as HIV patients, and chemotherapy patients.

Aim: However, since ICZ is a BCS Class II drug that has low solubility and high permeability, leads to low oral bioavailability.

View Article and Find Full Text PDF

Design and Process Considerations for Preparation of Modified Release Ivermectin and Praziquantel Tablets by Wet Granulation.

AAPS PharmSciTech

January 2025

University of Maryland, School of Pharmacy, Department of Pharmaceutical Sciences, 20 N Pine Street, Baltimore, Maryland, 21201, USA.

Dosage forms containing Ivermectin (IVER) and Praziquantel (PRAZ) are important combination drug products in animal health. Understanding the relationship between products with differing in vitro release characteristics and bioequivalence could facilitate generics. The goal of this study was to create granulations for each active ingredient, with similar release mechanisms, but substantially different in vitro release rates, and then compressing these granulations into tablets with differing release rates.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!